Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi

Journal of Infectious Diseases

Volumn 187, Issue 12, 2003, Pages 1870-1875

  Kublin, James G ^a,c,f   Cortese, Joseph F ^a   Njunju, Eric Mbindo ^e   Mukadam, Rabia A G ^c   Wirima, Jack J ^c   Kazembe, Peter N ^d   Djimdé, Abdoulaye A ^h   Kouriba, Bourema ^h   Taylor, Terrie E ^b,c   Plowe, Christopher V ^a,g  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MALAWI   (Malawi)

^d Lilongwe Central Hospital   (Malawi)

^e TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CHLOROQUINE; MOLECULAR MARKER; PROTOZOAL PROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; DRUG WITHDRAWAL; GENOTYPE; HUMAN; IN VITRO STUDY; MALARIA FALCIPARUM; MALAWI; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; PROTOZOAL GENETICS; SYMPTOM; TREATMENT OUTCOME;

ANIMALS; ANTIMALARIALS; CHILD; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALAWI; MALE; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TIME FACTORS;

EID: 0038239207     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375419     Document Type: Article

References (34)

1. Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993; 167:932-7.
2. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 2000; 5:755-64.
3. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861-71.
4. Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falcifarum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210-3.
5. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770-6.
6. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-9.
7. Djimdé A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257-63.
8. Plowe CV, Kublin JG, Doumbo OK. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resist Updats 1998; 1:389-96.
9. World Health Organization. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission: Report WHO/MAL/96-1077. Geneva: World Health Organization, 1996.
10. World Health Organization. In vitro micro-test (Mark III) for the assessment of the response of Plasmodium falciparum to chloroquine, mefioquine, quinine, sulfadoxine/pyrimethamine and amodiaquine. Report no. MAP/87.2. Geneva: World Health Organization, 1987.
11. Plowe CV, Doumbo OK, Djimde A, et al. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 2001; 64:242-6.
12. Mayor AG, Gomez-Olive X, Aponte JJ, et al. Prevalence of the K76T mutation in the putative Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene and its relation to chloroquine resistance in Mozambique. J Infect Dis 2001; 183:1413-6.
13. Plowe CV, Cortese JF, Djimdé A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine- sulfadoxine use and resistance. J Infect Dis 1997; 176:1590-6.
14. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185:380-8.
15. Duraisingh MT, Drakeley CJ, Muller O, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology 1997; 114:205-11.
16. Conway DJ, Roper C, Oduola AM, et al. High recombination rate in natural populations of Plasmodium falciparum. Proc Natl Acad Sci USA 1999; 96:4506-11.
17. Levin BR, Perrot V, Walker N. Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 2000; 154:985-97.
18. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001; 357:1325-8.
19. Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272: 1641-3.
20. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-9.
21. Jelinek T, Aida AO, Peyerl-Hoffmann G, et al. Diagnostic value of molecular markers in chloroquine-resistant falciparum malaria in Southern Mauritania. Am J Trop Med Hyg 2002; 67:449-53.
22. Heymann DL, Khoromana CO, Wirima JJ, Campbell CC. Comparative efficacy of alternative primary therapies for Plasmodium falciparum infections in Malawi. Trans R Soc Trop Med Hyg 1987; 81:722-4.
23. Verhoeff FH, Brabin BJ, Masache P, Kachale B, Kazembe P, van der Kaay HJ. Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. Ann Trop Med Parasitol 1997; 91:133-40.
24. Takechi M, Matsuo M, Ziba C, et al. Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children. Trop Med Int Health 2001; 6:429-34.
25. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770-6.
26. Durand R, Jafari S, Vauzelle J, Delabre J, Jesic Z, Le Bras J. Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum. Mol Biochem Parasitol 2001; 114:95-102.
27. Carlin JM, Vande Waa JA, Jensen JB, Akood MA. African serum interference in the determination of chloroquine sensitivity in Plasmodium falciparum. Z Parasitenkd 1984; 70:589-97.
28. Liu DQ, Liu RJ, Ren DX, et al. Changes in the resistance of Plasmodium falciparum to chloroquine in Hainan, China. Bull World Health Organ 1995; 73:483-6.
29. Schwenke A, Brandts C, Philipps J, Winkler S, Wernsdorfer WH, Kremsner PG. Declining chloroquine resistance of Plasmodium falciparum in Lambarene, Gabon from 1992 to 1998. Wien Klin Wochenschr 2001; 113:63-4.
30. Cortese JF, Caraballo A, Contreras CE, Plowe CV. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 2002; 186:999-1006.
31. Djimde A, Doumbo OK, Steketee RW, Plowe CV. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 2001; 358:890-1.
32. Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770-6.
33. Bijl HM, Kager J, Koetsier DW, van der Werf TS. Chloroquine- and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo: a pilot study in rural Zambia. Trop Med Int Health 2000; 5:692-5.
34. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.